Efficacy of combination therapy of pegylated interferon alfa-2b plus ribavirin for 48 weeks in chronic hepatitis C patients with serotype 1 high viral load: Results of multicenter trial in Tohoku area of Japan

Akio Miyasaka, Juichi Sakamoto, Shinsaku Fukuda, Takashi Goto, Hirohide Ohnishi, Yoshiyuki Ueno, Tooru Shimosegawa, Takafumi Saito, Sumio Kawata, Hiromasa Ohira, Masafumi Komatsu, Koich Abe, Kazuyuki Suzuki

Research output: Contribution to journalArticlepeer-review

Abstract

We estimated 256 chronic hepatitis C (C-CH) patients with serotype 1 high viral load who received pegylaed interferon alfa-2b and ribavirin for 48 weeks. All patients were assessed for efficacy, tolerance and safety. Discontinuation of therapy for adverse events was 17.8% (45/256) for 48 weeks and 53 patients showed mild or moderate adverse events. The sustained virological response (SVR) rate was 44.5% (114/256). The SVR rate was significantly higher in patients less than 56 years old than more than 56 years old and was tend to be lower in the patients who reduced peylated interferon alfa-2b, ribavirin or both dosage than patients who received full dose. In logistic regression analysis, four independent factors were significantly associated with SVR; body mass index (= or >23.5), platelet counts (= or >16.4μ/l), adherence to pegylaed interferon alfa-2b (= or >80%) until 12 weeks and adherence to ribavirin (= or >80%) until 12 weeks. In conclusion, these results suggest that the combination therapy with pegylaed interferon alfa-2b and ribavirin may be safety and tolerance for C-CH patients with serogroup1 high viral load.

Original languageEnglish
Pages (from-to)652-661
Number of pages10
JournalActa Hepatologica Japonica
Volume52
Issue number10
DOIs
Publication statusPublished - 2011

Keywords

  • Adherence
  • Chronic hepatitis C
  • Pegylaed interferon alfa-2b
  • Ribavirin
  • Serotype 1

ASJC Scopus subject areas

  • Hepatology

Fingerprint Dive into the research topics of 'Efficacy of combination therapy of pegylated interferon alfa-2b plus ribavirin for 48 weeks in chronic hepatitis C patients with serotype 1 high viral load: Results of multicenter trial in Tohoku area of Japan'. Together they form a unique fingerprint.

Cite this